Medesis Pharma S.A. (EPA:ALMDP)
France · Delayed Price · Currency is EUR 0.3500
0.00 (0.00%)
Inactive · Last trade price on May 14, 2025
Medesis Pharma Company Description
Medesis Pharma S.A. operates as a biopharmaceutical company.
The company’s products include NanoLithium (NP03) for the treatment of Alzheimer’s disease; NanosiRNA HD and NanoP42T to treat Huntington’s disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs.
It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma.
The company was founded in 2003 and is based in Montpellier, France.
Medesis Pharma S.A.
| Country | France |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Jean-Claude Maurel |
Contact Details
Address: LOrEe des Mas Montpellier, 34670 France | |
| Phone | 33 4 67 03 03 96 |
| Website | medesispharma.com |
Stock Details
| Ticker Symbol | ALMDP |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0010844464 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jean-Claude Maurel M.D., MHB | Chairman of the Management Board, Chief Executive Officer and President |
| Mario Alcaraz | Member of the Executive Board and General Secretary |